Phase I and II drug metabolizing enzymes (DME) and drug transporters are involved in the
absorption, distribution, metabolism as well as elimination of many therapeutic agents …

The aim of a PharmGKB VIP summary is to provide a simple overview of a gene with respect
to drug effects. In some cases, there may be extensive evidence of variants that have known …

Introduction: Gastrointestinal stromal tumors (GIST) and chronic myeloid leukemia (CML) are
two tumor types deeply different from each other. Despite the differences, these disorders …

In this paper, we first give an upper bound for the largest signless Laplacian eigenvalue of a
graph and find all the extremal graphs. Secondly, we consider the second-largest signless …

Introduction Imatinib mesylate (IM), a selective inhibitor of the BCR-ABL tyrosine kinase, is a
well-established first-line treatment for chronic myeloid leukemia (CML). IM is metabolized …

What is known and objective Imatinib mesylate is the first‐line drug for the treatment of
Philadelphia/bcr‐abl positive chronic myeloid leukaemia (CML). It is known to be …

CYP3A5 is a cytochrome P450 superfamily member which is involved in the metabolism of
drugs, steroid hormones, and other xenobiotics. Emerging evidences suggest that CYP3A5 …

Imatinib mesylate (IM), a tyrosine kinase inhibitor, is one of the first molecularly targeted
therapies to have been used in the clinic. It has proven to be efficient in the treatment of …

Background Imatinib has so far been the first-choice treatment in chronic myeloid leukemia
(CML) with excellent results. However, only a proportion of patients achieve major molecular …

Despite the excellent efficacy and improved clinical responses obtained with imatinib
mesylate (IM), development of resistance in a significant proportion of chronic myeloid …